Long-term Effect of Postoperative Radioactive Iodine Therapy on Parathyroid Function in Patients with Differentiated Thyroid Cancer

Overview

Journal Ann Nucl Med

Date 2024 Nov 4

PMID 39496869

Authors

Fatma Avci Merdin

Asena Gokcay Canpolat

Demet Corapcioglu

Cigdem Soydal

Mustafa Sahin

Affiliations

Soon will be listed here.

Abstract

Objective: The study aimed to assess the impact of postoperative radioactive iodine (RAI) therapy on parathyroid function in patients who underwent total or subtotal thyroidectomy for differentiated thyroid cancer (DTC).

Methods: Data from 150 patients treated with RAI for DTC and 76 patients with low-risk DTC not receiving RAI were retrospectively analyzed. Clinical characteristics, preoperative and 1-month postoperative biochemical parameters, and adjusted calcium, phosphorus, parathyroid hormone (PTH), and 25-hydroxyvitamin D3 (25-OH-D) levels at 3 months, 1 year, 3 years, and 5 years post-RAI (or in the low-risk group) were recorded.

Results: A total of 226 DTC patients were included in the study (80.5% female, mean age 42.7 ± 13.2 years). Total thyroidectomy was performed in 97.3% (n = 220) of patients, with central lymph node dissection (CLND) in 41.6% (n = 94). No significant preoperative differences in PTH, aCa, P, Mg, or 25-hydroxyvitamin D3 levels were observed. However, patients receiving ≥ 3.7 GBq (or 100 mCi) RAI (n = 70) had lower calcium and PTH levels at the end of the first year following RAI treatment (p = 0.048, p = 0.032). The non-RAI group showed significantly higher calcium levels at one month postoperatively (p = 0.031) and lower rates of CLND and neck dissection. No significant differences in biochemical parameters were found at the five-year follow-up, except for one patient who developed normocalcemic hyperparathyroidism after RAI.

Conclusion: High-dose RAI therapy may lead to transient decreases in calcium and PTH levels in the early post-treatment period. However, long-term parathyroid function appears to remain unaffected in DTC patients, regardless of the RAI dose administered. Nonetheless, close monitoring of calcium and PTH levels is recommended, particularly in the early post-treatment period, to promptly manage any potential transient hypoparathyroidism.

References

Rasmuson T, Tavelin B . Risk of parathyroid adenomas in patients with thyrotoxicosis exposed to radioactive iodine. Acta Oncol. 2006; 45(8):1059-61. DOI: 10.1080/02841860500516618. View

Esselstyn Jr C, SCHUMACHER O, Eversman J, Sheeler L, Levy W . Hyperparathyroidism after radioactive iodine therapy for Graves disease. Surgery. 1982; 92(5):811-3. View

Rosen I, Palmer J, ROWEN J, Luk S . Induction of hyperparathyroidism by radioactive iodine. Am J Surg. 1984; 148(4):441-5. DOI: 10.1016/0002-9610(84)90366-0. View

Eipe J, Johnson S, Kiamko R, BRONSKY D . Hypoparathyroidism following 131-I therapy for hyperthyroidism. Arch Intern Med. 1968; 121(3):270-2. View

Fulop M . Hypoparathyroidism after 131 I therapy. Ann Intern Med. 1971; 75(5):808. DOI: 10.7326/0003-4819-75-5-808_1. View

Winslow C, Meyers A . Hypocalcemia as a complication of radioiodine therapy. Am J Otolaryngol. 1998; 19(6):401-3. DOI: 10.1016/s0196-0709(98)90045-x. View

Zhang A, Li P, Liu Q, Peng S, Huang G, Song S . EFFECT OF POST-SURGICAL RAI THERAPY ON PARATHYROID FUNCTION IN PATIENTS WITH DIFFERENTIATED THYROID CANCER. Endocr Pract. 2020; 26(4):416-422. DOI: 10.4158/EP-2019-0398. View

Lin C, Doyle P, Tsan Y, Lee C, Wang J, Chen P . 131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study. Eur J Nucl Med Mol Imaging. 2013; 41(2):253-9. DOI: 10.1007/s00259-013-2541-5. View

Lamartina L, Grani G, Arvat E, Nervo A, Zatelli M, Rossi R . 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2). Endocr Relat Cancer. 2017; 25(3):L7-L11. DOI: 10.1530/ERC-17-0453. View

10.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

11.

Guven A, Salman S, Boztepe H, Yarman S, Tanakol R, Azizlerli H . Parathyroid changes after high dose radioactive iodine in patients with thyroid cancer. Ann Nucl Med. 2009; 23(5):437-41. DOI: 10.1007/s12149-009-0270-4. View

12.

Glazebrook G . Effect of decicurie doses of radioactive iodine 131 on parathyroid function. Am J Surg. 1987; 154(4):368-73. DOI: 10.1016/0002-9610(89)90006-8. View

13.

Colaco S, Si M, Reiff E, Clark O . Hyperparathyroidism after radioactive iodine therapy. Am J Surg. 2007; 194(3):323-7. DOI: 10.1016/j.amjsurg.2007.04.005. View

14.

Cohen J, Gierlowski T, Schneider A . A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. JAMA. 1990; 264(5):581-4. View

15.

Morgan W, Sowa M . Non-targeted bystander effects induced by ionizing radiation. Mutat Res. 2006; 616(1-2):159-64. DOI: 10.1016/j.mrfmmm.2006.11.009. View

16.

Bondeson A, Bondeson L, Thompson N . Hyperparathyroidism after treatment with radioactive iodine: not only a coincidence?. Surgery. 1989; 106(6):1025-7. View